SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending after finalizing its $250M acquisition of Ask Sage, a generative AI platform crucial for secure deployment in defense and regulated sectors. This strategic integration is igniting strong community optimism for future government contracts and growth, although ongoing discussions and postponements surrounding a key shareholder vote on authorized shares continue to shape investor sentiment.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics is trending due to its exceptionally low public float, positioning it as a prime candidate for a short squeeze. The community is actively discussing the company's significant cash reserves relative to its market valuation, fueling speculation about potential strategic alternatives like a merger. Many believe this combination of factors points to substantial untapped value and potential for rapid upward movement, drawing comparisons to other recent parabolic movers.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is trending due to intense community debate surrounding an upcoming shareholder meeting, where a significant increase in authorized shares is a key proposal, fueling investor concerns over potential dilution and perceived management self-interest given the stock's underperformance against Ethereum. While some investors view recent declines as a buying opportunity, anticipating future staking revenue and a broader market rebound, many others express strong bearish sentiment, criticizing leadership actions and questioning the company's financial strategy.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following its announcement of record December and Q4 2025 vehicle deliveries, surpassing key competitors. The community is buzzing with speculation about whether these strong delivery figures will finally translate into profitability in Q4 or 2026, and if the stock price will reflect the improving fundamentals amid ongoing frustration over perceived market manipulation. Many highlight the expanding battery swap network and multi-brand strategy as crucial long-term growth drivers.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to extreme recent volatility, including a significant price drop from earlier highs, which is happening alongside news of its blockchain technology expanding into luxury and fashion traceability. Community sentiment is sharply divided, with proponents highlighting its disruptive tech and potential for a short squeeze amidst a low float and high cost to borrow, while skeptics point to a history of reverse splits and ongoing dilution concerns.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending after announcing a strategic manufacturing partnership and a private placement that is expected to strengthen its balance sheet and scale production. This has ignited intense community discussion, with many anticipating a short squeeze fueled by its low public float, while others express caution regarding potential dilution from the private placement.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is trending amidst growing excitement over its recent defense and commercial space contract wins, coupled with a bullish analyst re-rating. The community sees RDW as an undervalued play, poised for a significant rally as high short interest and increasing capital inflows into the broader space and defense sectors drive conversation for the coming year.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is a major trending topic as the community anticipates upcoming Q4 delivery figures and discusses the potential for preferential treatment for shareholders in a future SpaceX IPO. Bullish investors are focusing on Tesla's AI and robotics advancements, along with energy sector growth, while bears express skepticism over past promises and concerns about declining EV sales amidst increasing competition.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is trending as the community highlights its upcoming merger with Cartiga, a litigation finance platform praised for its business model. The stock is gaining significant attention as a low-float play, with many drawing parallels to other recent volatile SPAC moves. Investors are actively discussing the potential for a substantial short squeeze and a breakout run, anticipating strong momentum in upcoming trading.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is highly trending as its community buzzes with anticipation for a significant rebound, driven by the perceived end of tax loss selling and the onset of a new year. Enthusiastic holders are urging others to accumulate, hoping for an upcoming "altseason" and potential future utility with X. However, a strong counter-narrative persists, with many skeptics continuing to label it a volatile "shitcoin" unlikely to sustain gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Here's Why

Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 4.4% - Should You Sell...

Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 4.5% - Here's Why

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.5% - Here's What Happened...

Nasdaq-listed shares of Tiziana Life Sciences (TLSA) rose 2% by Thursday afternoon after the company announced that it will advance its second asset, TZLS-501, and pursue non-dilutive funding strategies for its development.TZLS-501 is a fully human anti-IL-6 receptor monoclonal antibody or a biological therapy that blocks the action of interleukin-6 protein. Tiziana <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-advance-tzls-501-its-fully-human-il-6r-monoclonal">sees</a> potential to develop it as a monotherapy or in combination with its lead candidate, as well as with other anti-inflammatory and anti-infective agents.The company stated that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions where excessive IL-6 signaling plays a central role, such as rheumatoid arthritis (RA), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), systemic lupus erythematosus, and various types of cancer.The company also stated that it will continue to advance intranasal Foralumab as its lead program, not diverting resources or focus from it. The firm is currently evaluating Foralumab in the treatment of multiple sclerosis, a chronic autoimmune disease in which the immune system attacks the protective myelin sheath surrounding nerve cells in the brain and spinal cord, causing numbness, vision problems, muscle weakness, balance issues, and fatigue.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TLSA">TLSA stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:573/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_1_37_07_PM_png_487989b630.webp" alt="TLSA's Sentiment Meter and Message Volume as of 1:37 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="573" height="66"><figcaption>TLSA's Sentiment Meter and Message Volume as of 1:37 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes that the stock has “so much potential.”<stembedurl>https://stocktwits.com/GoCubsGo1124/message/629975723</stembedurl>Tiziana said on Thursday that the <a href="https://stocktwits.com/news-articles/markets/equity/tourmaline-stock-rockets-pre-market-after-novartis-buy-out-announcement/chwKP7BRdt5">recent acquisition</a> of Tourmaline Bio by Novartis for about $1.4 billion validates the importance of IL-6 therapeutics. The acquisition, announced earlier in September, includes Tourmaline’s Pacibekitug, a monoclonal antibody that targets IL-6, which is being evaluated as a treatment option for atherosclerotic cardiovascular disease.“With recent market developments, we feel it is an opportune time to explore TZLS-501’s development,” said Tiziana CEO Ivor Elrifi.TLSA stock nearly tripled in value this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-terminates-study-of-bimagrumab-in-obesity/chDlEmYR34I">Eli Lilly Terminates A Study Of Bimagrumab In Obesity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’

Tiziana said that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions.

Equity

Tiziana said that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions.


AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer’s. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

TLSA
Tiziana Life Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results:

Historical Earnings

Latest TLSA News

TLSATiziana Life Sciences Ltd